This site is intended for Healthcare Professionals only.

Trifluoperazine supplies to resume in mid-September


Share post:

The Trifluoperazine 1mg/5ml syrup will remain out of stock, according to an update from the Pharmaceutical Services Negotiating Committee (PSNC) the supplies are expected to resume mid-September 2021.

Earlier, the Department of Health and Social Care (DHSC) had issued a medicine supply notification for Trifluoperazine 1mg/5ml syrup, stating it would remain out of stock until April 2021 which has been further extended till mid of September.

However, Trifluoperazine 1mg and 5mg tablets were available to support an increase in demand.

Further to support any increase in demand, specials manufacturers had confirmed to manufacture the medicine in 1mg/5ml oral suspension.

Anyone prescribing a product that is not licensed in the UK must indicate on the FP10 prescription that an unlicensed product is required. This can be done by annotating the prescription with the wording “Special Order”, as per the DHSC notification.

Currently, the medicine is not listed on the NHS Dictionary of Medicines and Devices (dm+d) for prescribers.

However, if a prescriber wishes to prescribe an unlicensed import, a paper prescription should be issued as ‘Trifluoperazine 1mg/5ml oral suspension (Special Order)‘and endorsed by the pharmacy as a non-Part VIIIB special.

The paper should also have a mention of amount dispensed over pack size used, invoice price per pack size, manufacturers’/importers’ Medicines and Healthcare Products Regulatory Agency (MHRA) licence number, batch number of the product supplied.


Please enter your comment!
Please enter your name here

Current Issue June 2024

Related articles

ABPI: Increased pharma exports could boost GDP by £16.3 billion

ABPI urges political leaders to enhance healthcare and economic growth through strategic partnership The Association of the British Pharmaceutical...

The Importance Of Expanding Access To Dental Care For Rural And Undeserved Populations

In many rural areas and underserved neighborhoods, a critical issue is quietly emerging. Although often overlooked, its effects...

BGMA: More than 50% of UK generics face shortages without licensed alternatives

Brexit blamed by BGMA CE, Mark Samuels, as UK faces critical shortages in generic drug supply A recent report...

Paul Burden elected BGMA Vice-Chair, bringing 25 years of industry leadership

Veteran of off-patent sector to drive strategic engagement and patient access initiatives at BGMA The British Generic Manufacturers Association...